| __timestamp | Alnylam Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 20140000 |
| Thursday, January 1, 2015 | 60610000 | 37173000 |
| Friday, January 1, 2016 | 89354000 | 48616000 |
| Sunday, January 1, 2017 | 199365000 | 108488000 |
| Monday, January 1, 2018 | 382359000 | 244622000 |
| Tuesday, January 1, 2019 | 479005000 | 287000000 |
| Wednesday, January 1, 2020 | 588420000 | 354000000 |
| Friday, January 1, 2021 | 620639000 | 186000000 |
| Saturday, January 1, 2022 | 770658000 | 151000000 |
| Sunday, January 1, 2023 | 795646000 | 232600000 |
| Monday, January 1, 2024 | 975526000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, effective cost management is crucial for sustaining growth and innovation. Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. have been at the forefront of this industry, each with unique strategies for managing Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and investment in new therapies. In contrast, Ionis Pharmaceuticals exhibited a more moderate increase of around 1,050%, indicating a more conservative approach. Notably, Alnylam's expenses peaked in 2023, reaching nearly four times that of Ionis, highlighting its commitment to scaling operations.
These trends underscore the diverse strategies employed by biotech firms in balancing growth with financial prudence, offering valuable insights for investors and industry stakeholders alike.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Ionis Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights
Ionis Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends